Monday, November 13, 2017 12:02:20 PM
Please do some research on 351a and 351k. If they pursue 351a and wish to bridge to the Korean data then the major issue is not that much the bridging but the quality of the Korean data.
i.e. How far did Hanmi go with clinical trials? (my understanding is not far past phase 1). Were the clinical trials of acceptable quality to meet FDA standards? (i.e. even if they bridge, will the FDA accept the data?). How about CMC? (i.e. analytical methods, process, scale-up etc?. I assume you know that in Biologics this is much much more important than in small molecules).
The old "magician" my be good at confusing the less sophisticated but reality will catch up with him...Unless serendipity helps again the way it did with Levoleucovorin a few years ago...
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM